欧美大色I日本婷婷I操屄亚洲I国产精品久久久久永久免费看I免费电视剧网站I国内精品网站Ixxxx77777I三级动图I丁香九月激情综合I欧美A一Igogogo在线观看免费高清完整版I啪啪AV′I亚洲va男人天堂I日本xxxxavI免费网站色I超碰精品男人的天堂I国精产品一区一区三区有vaI国产综合久久777777麻豆

Welcome to Linuo Group!HomeBusiness License
  • CN

  • WeChat

  • Mobile Site

  • Search

力諾資訊

Keyuan Pharma Wins 2025 Forbes China Industry Development Innovative Brand Award

2025.04.02

Shandong Keyuan Pharmaceutical Co., Ltd. has been awarded the 2025 Forbes China Industry Development Innovative Brand Award at the 2025 Forbes China Industry Development Pioneers Selection held in Shanghai on March 22nd, in recognition of its exceptional innovation capabilities and significant industry influence.

The accolade not only represents high recognition of Keyuan Pharma's years of dedicated efforts in the field of chemical APIs and preparations but also stands as a powerful testament to its leapfrog development driven by innovation amid the adjustments in the global industrial landscape.

Jointly initiated by Frost & Sullivan, a world-renowned growth consulting firm, and Forbes China Group, the 2025 Forbes China Industry Development Pioneers Selection aims to identify outstanding enterprises and individuals in key sectors such as new energy, AI technology, mass consumption, and biomedicine that are driving industry transformation with an innovative spirit. Keyuan Pharma's success in standing out this time underscores its prominent position in the chemical drug sector.

Founded in 2004, Keyuan Pharmaceutical has focused on the R&D, production, and sales of chemical APIs and preparations. It has established three core product lines: anti-diabetic, cardiovascular, and anesthetic drugs, and ranks as a backbone enterprise in the field of chemical synthetic drugs in Shandong Province.

Innovation is the core driving force behind Keyuan Pharma's development. The company has continuously increased its R&D investment, actively explored cutting-edge technologies, and improved its innovation system. Recently, Keyuan Pharma obtained the utility model patent authorization for "a raw material preliminary processing and drying device for metformin hydrochloride processing," marking the fourth patent authorization it has received this year. A series of patent achievements have provided solid support for improving product quality, enhancing production efficiency, and controlling costs, helping the company gain an edge in the fierce market competition.